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Reduced activity of brain α-ketoglutarate dehydrogenase complex (KGDHC) occurs in a number of neurodegenerative diseases
like Parkinson’s disease and Alzheimer’s disease. In order to quantify the relation between diminished KGDHC activity and the
mitochondrial ATP generation, redox state, transmembrane potential, and generation of reactive oxygen species (ROS) by the
respiratory chain (RC), we developed a detailed kinetic model. Model simulations revealed a threshold-like decline of the ATP
production rate at about 60% inhibition of KGDHC accompanied by a signiﬁcant increase of the mitochondrial membrane
potential. By contrast, progressive inhibition of the enzyme aconitase had only little impact on these mitochondrial parameters. As
KGDHC is susceptible to ROS-dependent inactivation, we also investigated the reduction state of those sites of the RC proposed to
be involved in ROS production. The reduction state of all sites except one decreased with increasing degree of KGDHC inhibition
suggesting an ROS-reducing eﬀect of KGDHC inhibition. Our model underpins the important role of reduced KGDHC activity in
the energetic breakdown of neuronal cells during development of neurodegenerative diseases.
1.Introduction
A decline in the activity of the thiamine-dependent enzyme
complex α-ketoglutarate dehydrogenase (KGDHC) in brain
has been reported for numerous age-related neurodegenera-
tivediseases[1,2].InAlzheimer’sdisease,reductionsinbrain
KGDHCactivityrangefrom25to75%[3–7]andarestrongly
correlated to the decline in cognition [8]. Variations in the
amounts of KGDHC between diﬀerent brain regions [9, 10]
may account for the brain region-speciﬁc diﬀerent vulner-
abilities. Neurons containing high amount of KGDHC like
cholinergic neurons in the nucleus basalis are particularly
susceptible to Alzheimer’s disease [3, 11].
The citric acid cycle is catalyzed by eight enzymes,
among which KGDHC has the lowest activity [12]. Thus,
KGDHC is considered one of the rate-limiting enzymes in
the tricarbonic acid cycle (TCAC). It has been proposed
that reduced activity of this enzyme complex initiates
a cascade of adverse processes, including metabolic failure,
mitochondrial membrane depolarization, calcium overload,
and cytochrome c release, eventfully leading to cell death
[13]. The same cascade has been implicated in the massive
death of dopaminergic neurons in the substantia nigra of
patients with Parkinson’s disease [14].
The molecular mechanisms underlying the age-
dependent loss of brain KGDHC activity remain elusive.
Inactivation of the enzyme complex by reactive oxygen
species (ROS) is one possible explanation as KGDHC and
the aconitase have been shown to be the main targets of ROS
in the citric acid cycle [15].
To further clarify the implications of reduced activities
of the TCAC enzymes KGDHC and aconitase for the mito-
chondrial energy metabolism and the formation of ROS by
the respiratory chain, we developed and applied a detailed
kinetic model encompassing the TCAC, the respiratory
chain (RC), translocation of adenine nucleotides between2 International Journal of Cell Biology
mitochondrial matrix and the cytosol, oxidative phospho-
rylation, and ion transport across the inner mitochondrial
membrane. The submodel of the RC describes the electron
transport as a multistep process whereby some of the
intermediate redox sites allow electron transfer to molecular
oxygen under formation of the superoxide anion (ROS).
2. Model
The reaction scheme of the kinetic model is shown in
Figure 1. It comprises the reactions of the citric acid cycle,
the respiratory chain, oxidative phosphorylation, mitochon-
drial ATP generation, the exchange of adenine nucleotides
exchange between mitochondrial matrix and cytosol, and
the transport of small ions across the inner mitochondrial
membrane. Since more than 90 percent of the ATP produced
in neuronal cells is derived from oxidative phosphorylation,
we omitted the glycolytic pathway while putting the supply
of pyruvate and its uptake into the mitochondrial matrix to
aﬁ x e dv a l u e .
The kinetic model focuses on the mitochondrial-derived
ATP production and is compartmentalized into cytosol and
mitochondria. The model consists of 184 state variables
describing the neuronal citric acid cycle, the respiratory
chain,theoxidativephosphorylation,themitochondrialATP
generation, the nucleotide exchange between the mitochon-
drial matrix and the cytosol, and the electrophysiological
coupling between the pathways. Since more than 90 percent
of the ATP produced in neuronal cells is derived from
oxidative phosphorylation [16], we omitted the glycolytic
pathway. It is assumed that the glycolytic pathway is not
limiting in the provision of pyruvate, so cytosolic pyruvate
was kept constant. Since cytosolic redox equivalents are not
considered, the aspartate/malate shuttle is not part of the
model. Mitochondrial calcium is a potent activator of PDH,
IDH, and KGDHC. Mitochondrial calcium concentration
does vary in a physiological range depending on mito-
chondrial membrane potential [17, 18]. For simplicity, we
modeled the mitochondrial calcium concentration as linear
function of the mitochondrial membrane potential.
In order to include the potential formation of ROS in our
model, we developed a detailed submodel of the respiratory
chain that takes into account the substructure of complexes I
andIIIcomposedofseveralprostheticgroupsandironsulfur
clusters (see Figure 2).
The functional parts of complex I are the ﬂavine
mononucleotide (FMN), eight iron-sulfur clusters (i.e., N3,
N1a, N1b, N4, N5, N6a, N6b, and N2), and the docking
site for ubiquinone. FMN accepts two electrons from
NADH forming fully reduced ﬂavine. The electrons are
then successively transferred to the subsequent iron-sulfur
clusters. When the ﬁrst electron is moved, the ﬂavin exists
as a ﬂavin radical. From the terminal iron-sulfur cluster
N2, the electron is transferred to ubiquinone forming a
bound semiubiquinone (SQ). A second electron transported
from N2 to SQ generates ubiquinol that is released from
complex I. This electron transfer takes place in the arm of
complex I extending into the mitochondrial matrix, whereas
the ubiquinone/ubiquinol conversion is located at the n-site
of the inner mitochondria membrane. The transfer of one
electron from N6b to N2 and from N2 to ubiquinone or
semiubiquinone is linked with the export of one proton
from the matrix into the cytosol. In the model, the electron
state of complex I is represented as an array of integer
numbers where the reduction of the ﬂavinmononucleotide,
each iron-sulfur cluster, and the existence of the bound
semiubiquinone are encoded. All reactions are modeled as
reversible mass action kinetics. Model simulations show that
lumping together the complexes N1b, N4, N5, N6a, and N6b
gives similar results as the full model but reduces the number
of state variables from 1536 to 96.
Each state of complex III is described as an array
describing the reduction and binding states of its functional
parts: cytochrome c1 (c1), the iron sulfur cluster (Fe-S),
the binding site for ubisemiquinone at p-site (SQp), the
low b-type heme (bL), the high b-type heme (bH), and
the binding site for ubisemiquinone at n-site (SQn). The
spatial arrangement of these redox carriers enables the
transduction of two electrons from one molecule ubiquinol
totwomoleculesofcytochromecviatheq-cyclemechanism.
Ubiquinol diﬀuses from n- to p-site, reacts with oxidized
Fe-S, thereby reducing it, and generates a bound semi-
ubiquinon at p-site. The bound semi-ubiquinon reduces bL
atp-siteandfreeubiquinondiﬀusesbackton-site.Onlyafter
release of ubiquinone from p-site, reduced Fe-S is able to
transfer its electron to oxidized cytochrome c1, which passes
itontocytochrome c.ThereducedbL transfersitselectronto
oxidized bH.T h er e d u c e db H reacts with n-site ubiquinone
to bound semi-ubiquinon. In a second round, reduced bH
transfers its electron to bound semi-ubiquinon. In this way
one electron is recycled in each turnaround of ubiquinol,
and two protons are transferred from the mitochondrial
matrix to the intermembrane space/cytosol per electron
transferred to cytochrome c. Importantly, it is assumed that
electrons are transferred from ubiquinol at p-side in a two-
step process, ﬁrst reducing the Fe-S and binding of SQp and
afterward reducing bL,a n dr e l e a s eo fQ p.A sl o n ga sS Q p is
bound, Fe-S cannot transfer the electron to c1. This gives 48
state variable and 88 reactions for complex III. All electron
transitions in complexes I and III are modeled as reversible
mass action kinetics. For further details, see supplemental
information in Supplementary Material available online at
doi:10.1155/2012/757594.
While kinetic models of the citric acid cycle are available
for heart and liver mitochondria [19], we developed a model
for brain tissue. Our submodel of the respiratory chain
extends existing models for complex III [20] by inclusion
of cytochrome c1 and SQn into the state space and detailed
modeling of complex I.
The detailed kinetic equations for the reactions and
transporters (see supplemental information) are speciﬁc for
neuronal and brain tissue and based on extensive literature
research. Vmax values for the reactions were determined by
ﬁtting simulated metabolite concentrations to experimen-
tally determined values.
The model was implemented in MATLAB (the Math-
Works, version R2011b). The extended model of complex I
of the respiratory chain was implemented in C++ (MicrosoftInternational Journal of Cell Biology 3
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Figure 1: Schematic of the mathematical model. Pyruvate (Pyr) is the only substrate of the TCA cycle. Pyruvate is decarboxylated by
pyruvate dehydrogenase (PDH) to acetyl-CoA (ACoA), which is then condensed with oxaloacetate (OA) to citrate (Cit) via the citrate
synthase (CS). Citrate is converted to isocitrate (IsoCit) by the aconitase (AC), which is further converted to α-ketoglutarate (aKG) via
the isocitrate dehydrogenase (IDH) producing NADH from NAD in the process. The α-ketogluterate dehydrogenase complex (KGDHC)
catalyses the reaction of α-ketogluterate with Coenzyme A to succinyl-CoA (SucCoA) under reduction of NAD to NADH. Succinyl-CoA is
further metabolized by succinyl-CoA synthase (SCS) to succinate (Suc) by phosphorylating ADP to ATP (substrate-chain phosphorylation).
Succinate is dehydrogenated to fumarate (Fum) by the succinate dehydrogenase (SDH, complex II) reducing ubiquinone to ubiquinol (see
legendofFigure2).Fumerase(FUM)convertsfumeratetomalate(Mal),whichisoxidizedbymalatedehydrogenase(MDH)againproducing
one NADH and regenerating the initial oxalacetate so the cycle can start over again. In summary, PDH and the TCA cycle produce one
ATP from ADP, one ubiquinol from ubiquinone, and four NADHs from NAD while oxidizing one pyruvate to three CO2. Oxidation of
NADH and/or succinate in the respiratory chain, is coupled to transmembrane proton pumping which generates a proton gradient and
a mitochondrial membrane potential. The proton gradient is used to fuel pyruvate uptake from the cytosol into the matrix via pyruvate
transporter, pumping of sodium, potassium from the matrix into the intermembrane space/cytosol, phosphate transport from the cytosol
into the matrix space, and ATP generation by the F0F1-ATPase. The mitochondrial membrane potential drives the ATP/ADP exchange
between the matrix and the intermembrane space/cytosol. The model also comprises the passive exchange of protons, sodium, potassium
and chloride between the matrix and the intermembrane space/cytosol driven by electrodiﬀusion as well as the mitochondrial membrane
potential. Cytosolic ATP is hydrolyzed to ADP and phosphate to meet the energy demand of the cell.4 International Journal of Cell Biology
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Figure 2:Schematicoftherespiratorychain.Therespiratorychain:incomplexI,NADHisoxidizedtoNAD,whilefourprotonsarepumped
from the mitochondrial matrix into the intermembrane space/cytosol. Concomitantly ubiquinon (Q), residing in the inner membranous
space, is reduced to ubiquinol (QH2) along with the uptake of two matrix protons. In Complex II, succinate is oxidized to fumarate while
ubiquinon is reduced to ubiquinol. In this reduction two protons are taken up from the matrix space, but no protons are pumped across
the mitochondrial membrane. In complex III, innermembranous ubiquinol is oxidized to ubiquinon. Via the q-cycle mechanism, two
protons are taken up from the matrix space, and four protons are released into the inter membrane space/cytosol. The two electrons are
consecutively transferred via Fe-S cluster to cytochrome c1 and reduce two molecules of cytochrome c. In complex IV, two molecules of
reduced cytochrome c are oxidized, and oxygen is reduced to water along with the transduction of two protons from the matrix space
into the inter membrane space/cytosol. With either NADH or succinate as substrates, the respiratory chain pumps ten and six protons,
respectively, from the matrix space to the inter membrane space/cytosol, and one molecule of water is formed.
Visual C++ 2008 Express Edition) and integrated with help
of the ODE integration package CVODE (SUNDIALS). The
developed source code can be provided on request.
3. Results
3.1. Analysis of Normal Mitochondrial Energy Metabolism.
First, we deﬁned a normal reference state where the cytosolic
ATP consumption rate, which is equal to the mitochondrial
ATP production rate under steady-state conditions, amounts
to about 30% of the maximal consumption rate and where
in concordance with experimental data [30–32] 24% of the
proton gradient is utilized by the proton leak of the inner
mitochondrial membrane, 16% by pumping of potassium
ions and 60% by the FoF1-ATPase and phosphate uptake.
Next, we calibrated our model (unknown Vmax values) such
thatmeasuredintramitochondrialmetaboliteconcentrations
(Figure 3, green bars) were reproduced. We then varied the
ATP consumption rate up to its maximal possible value and
calculated steady-state metabolite concentrations (Figure 3,
blue bars).
To check the reliability of our model, we compared load-
dependent changes of further model parameters with exper-
imental observation reported for various tissues (Figure 4).
The membrane potential is remarkably stable between
−150mV and −120mV over a wide range of ATP con-
sumption rates [33]. However, beyond a 2.5-fold increase
of the ATP consumption rate, a small further increase in
the ATP consumption rate was accompanied by a large drop
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Figure 3:Comparisonofsimulatedandexperimentallydetermined
concentrations of TCAC intermediates. Green bars indicate the
concentration range of reported experimental values [21–29]. Blue
bars (normal state) and red bars (50% inhibition of KGDHC)
indicatevariationsofconcentrationwhenvaryingtheenergeticload
between 33% and 100% of maximum.
in the membrane potential, hinting to metabolic failure.
The mitochondrial redox potential (expressed through the
NADH/NAD ratio) showed a quasilinear decline from 0.3
to 0.1 for ATP consumption rates up to the 2.5-fold ofInternational Journal of Cell Biology 5
V
m
m
 
(
m
V
)
−40
−60
−80
−100
−120
−140
−160
0 50 100 150 200 250 300 350
ATP production (% of normal)
(a)
0 50 100 150 200 250 300 350
ATP production (% of normal)
N
A
D
H
/
N
A
D
+
r
a
t
i
o
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
O
2
c
o
n
s
u
m
p
t
i
o
n
 
(
%
 
o
f
 
n
o
r
m
a
l
)
250
200
150
100
50
(b)
0 50 100 150 200 250 300 350
ATP production (% of normal)
100
80
60
40
20
H
u
s
e
(
%
 
o
f
 
H
p
u
m
p
e
d
)
(c)
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
m
M
)
1
0.8
0.6
0.4
0.2
0
0 50 100 150 200 250 300 350
ATP production (% of normal)
(d)
Figure 4: System characteristics under energetic challenge. Energetic demand was varied and behaviour of system variables determined.
(a) mitochondrial membrane potential; (b) blue NADH to NAD ratio, red oxygen consumption rate; (c) share of created proton gradient
used for ATP synthesis; (d) blue: ubiquinon at p-site, green: ubiquinol at n-site, red: ubiquinon at n-site, black: ubiquinol at p-site. ATP
production and oxygen consumption are normalized to the reference state of the system.
the normal. Concurrently, the oxygen consumption rate
doubled. The fact that oxygen consumption only doubled
at threefold increased ATP consumption is accounted for
by increased eﬃciency of ATP production, that is, the share
of ATP generation in the utilization of the proton gradient
increases from initially 60% to over 90% (Figure 4(c)). The
total ubiquinol to ubiquinon ratio (at n-site + p-site) varied
between 1.5 and about 0.5, in agreement with experimental
data [29]. At the mitochondrial p-site, this ratio dropped
from about 1 to zero at maximal indicating that ubiquinol
diﬀusion becomes rate limiting at high ATP consumption
rates [34].
Since multiple sites for mitochondrial ROS production
in complex I and complex III have been suggested in the lit-
erature, we monitored the occupation states of the disputed
ROS producing sites at varying ATP consumption rate (see
Figure 5). From our model simulations, we concluded that
the fully reduced ﬂavin, the semi-ubiquinone bound at n-
site in complex I, and the semiubiquinone bound a t p-site
in complex III are in agreement with expected dependencies
on the membrane potential, while the ﬂavin radical and the
semiubiquinone at p-site can be ruled out as main ROS
producers.
3.2. Analysis of Mitochondrial Energy Metabolism at Reduced
KGDHC Activities. Next, we investigated the eﬀects of
KGDHC and aconitase inhibition on the energy metabolism.
Simulations were performed with increasing degree of
inhibition of the KGDHC from 0 to 70% (see Figure 6).
The maximal ATP production capacity decreased very slowly
until about 50% inhibition of the enzyme. Higher inhibition
resulted at ﬁrst in an approximately linear decrease of the
maximal ATP production capacity and ﬁnally also in a linear
reduction of the ATP production rate in the reference state,
that is, the energy demand of the normal load state can
be satisﬁed until about 60% inhibition. At an inhibition
of about 70%, the system is close to collapse as can be
seen by the highly depolarized membrane potential. Suc-
cessive depletion of NADH (green curve) caused depletion
of reduced cytochrome c (black curve) in a nonlinear
manner which is ultimately responsible for the metabolic
failure seen at high inhibition states. Notably, as long as
reduced cytochrome c is not fully exhausted, the membrane
potential can be kept close to the reference value. Caution
must be used at interpreting the curves in regimes with
strongly depolarized mitochondrial membrane (> −80mV),
since mechanisms not modeled (like initiation of apoptotic
pathway/transition pore opening) are likely to dominate the
cellular behavior.
There occurred also profound shifts in the metabolite
concentrations of the citric acid cycle intermediates. Figure 3
shows the range of the citric acid cycle intermediates under
varied energetic load conditions at 50% inhibition of the
KGDHC (red bars). A-ketoglutarate was vastly increased and
thus partially compensated for the loss in enzyme activity
through higher substrate availability. Other metabolites of
the TCAC had lower concentrations compared to the normal
case.6 International Journal of Cell Biology
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Figure 5: Potential ROS producing states in the RC. ROS producing states of complex I ((a) and (b)) and complex III ((c) and (d))
are depicted versus the mitochondrial membrane potential ((a) and (c)) or the ATP production rate. Red: fully reduced ﬂavin, green:
ﬂavin radical, blue: semi-ubiquinon at n-site bound to the respective complex, black: semi-ubiquinon at p-site bound to complex III. ATP
production and occupation of ROS producing states are normalized to the reference state of the system.
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The dependence of the mitochondrial membrane poten-
tial on the ATP consumption rate at diﬀerent inhibitions of
the KGDHC is shown in Figure 7. At moderate inhibition of
the KGDHC < 30%, the increase of the membrane potential
was only 20mV up to 2.5-fold elevated energetic load, that
is, a signiﬁcant rise of the membrane potential occurred only
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Figure 7: Mitochondrial membrane potential characteristics at
inhibition of KGDHC. Mitochondrial membrane potential versus
the ATP production rate at diﬀerent inhibition levels of KGDHC.
Dotted line: −80mV membrane potential level.
at very high energetic load. At KGDHC inhibition of about
60%, themembranepotential wasalreadyelevated atnormal
ATP consumption rate, and the membrane depolarized atInternational Journal of Cell Biology 7
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much smaller increase of the ATP demand. Given pathologi-
calstatesofmitochondriatooccuratvaluesofthemembrane
potential above −80mV (dotted line in Figure 7), increasing
KGDHC inhibition of the membrane potential resulted in a
dramatic reduction of the tolerable maximal energetic load
and successive membrane depolarization at normal energy
demand.
The redox state of the RC and thus the residual energetic
capacity of the mitochondrion is common level. Figure 8
shows the combined impact of KGDHC inhibition and ener-
getic load on the mitochondrial NADH level. Generally, pro-
gressiveinhibitionoftheKGDHCisequivalenttoprogressive
increase of energetic load. For example, relative inhibition
of about 40% has the same eﬀect as a 1.5-fold increase of
the energetic load by the mitochondrial NADH. The eﬀect of
KGDHC and aconitase inhibition on mitochondrial NADH
content has been determined experimentally [15]. Figure 9
demonstrates that our simulations are in good concordance
with these experimental data. Inhibition of the KGDHC
has a much stronger eﬀect on the NADH content than
inhibition of the aconitase. Whereas half-reduction of the
NADHlevelisalreadyachievedwithabout40%inhibitionof
the KGDHC, the same eﬀect requires about 95% inhibition
of the aconitase.
3.3. ROS Production in the Respiratory Chain at Inhibited
KGDHC. Next, we investigated the inﬂuence of KGDHC
inhibition on ROS generation by the RC. To this end, we
calculated the occupation state of ROS generating sites in the
presence of KGDHC inhibition. Since our simulation of the
normalcasesuggestedthattheﬂavinradicalincomplexIand
the semiubiquinone at n-site in complex III can be discarded
as major ROS generating sites, only the fully reduced ﬂavin,
the semiubiquinone bound at n-site of complex I, and the
semiubiquinone bound at p-site of complex III are shown.
With increasing degree of KGDHC inhibition, there was a
remarkable reduction in the occupation state of the fully
reduced ﬂavin in complex I as well as SQp of complex
III at all workloads (see Figure 10), while the changes of
SQn of complex I were negligibly small. Above 2.5-fold
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Figure 9: NADH level comparison experiment and simulation.
Experimental determined NADH level as black points with error
bars at diﬀerent inhibition levels of KGDHC and aconitase (data
from[15]).Diﬀerentcoloured curvesvary inthebasalATPdemand
of the system from low (blue) to increased (black). Green curves
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are normalized to the NADH level without enzyme inhibition
respective to the ATP demand.
increase of the energetic load corresponding to a rise of
the membrane potential above −100mV, the RC is almost
completely oxidized so that additional KGDHC inhibition
has only a marginal eﬀect on the occupation state of the
considered ROS generating sites.
4. Discussion
Decreased KGDHC activity in neuronal cells of the brain is
associated with a number of neurodegenerative diseases. To
understandtheimpactofreducedKGDHConthemitochon-
drial energy metabolism of neurons, we developed a detailed
mathematical model comprising the central components of
mitochondrial ATP generation.
In agreement with experimental ﬁndings, our model
simulations showed a steady decline of the mitochondrial
NADH level with progressive KGDHC inhibition, whereas
up to 95% inhibition of the aconitase had virtually no
impact. This ﬁnding underpins the notion of KGDHC to
be a rate-limiting enzyme of the TCAC. Decline of NADH
ﬂuorescence at inhibition of KGDHC has been considered
to be indicative for a reduced ATP-generating capacity of
mitochondria [15]. The advantage of our mathematical
model is to enable predictions of the relationship between
NADH decline and ATP production rate. These simulations
suggest that a reduced NADH content does not translate
linearly to reduced energy production. This is due to a
compensatory change in the level of TCAC intermediates
upon KGDHC inhibition, thus rendering the ﬂux through
the TCAC almost constant over a wide range of inhibition
at normal or moderately enhanced energetic workload.
Increased akg levels activate the remaining intact KGDHC
to reestablish the original ﬂux through the enzyme. This
leads to an increased akg content (see Figure 3), a marker for
KGDHC impairment, since akg levels are also elevated in the
blood/urine. Since akg is in equilibrium with glutamate by a
deaminase reaction, this might lead to glutamate poisoning,8 International Journal of Cell Biology
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Figure 10: ROS production at inhibition of KGDHC. Levels of fully reduced ﬂavin ((a) and (b)), semi-ubiquinone at n-site bound to
complex I ((c) and (d)) and semi-ubiquinone at p-site bound to complex III ((e) and (f)) at various inhibitions (a) of KGDHC. The levels
are depicted versus the mitochondrial membrane potential ((a), (c), and (e)) and the ATP production rate ((b), (d) and (f)). Values except
membrane potential are normalized to the reference state.
another pathological feature associate with KGDHC inhibi-
tion [35].
Our simulation also revealed that the impairment of
the energy metabolism depends on the functional state
of the neuron. At high inhibition and/or high energetic
workload, the energetic output is severely compromised, and
functionality may not be maintained. This goes along with a
marked membrane depolarization.
There is striking evidence for a correlation between
reduced KGDHC activity and the loss of glutamatergic
neurons seen for example, in Alzheimer’s and Parkinson’s
disease [11]. Programmed cell death through the apoptotic
pathway requires the simultaneous occurrence of three
diﬀerent events: depolarization of the mitochondrial mem-
branepotential,lowintramitochondrialATPconcentrations,
and a mitochondrial overload with calcium. The ﬁrst two
conditions are fulﬁlled when neurons with reduced KGDHC
activity are challenged with high ATP demand that normally
can be accomplished by the cell. When the cytosolic ATP
levels are low, calcium is not suﬃciently pumped out
of the cell into the extracellular space, and the resulting
increased cytosolic calcium concentration ﬁnally leads to
mitochondrial calcium overload. Thus, strongly reduced
KGHDC activity might directly lead to apoptosis.International Journal of Cell Biology 9
One of the peculiarities of neurodegenerative diseases
is the strong age dependence. It is believed that the accu-
mulation of mitochondrial damage through ROS is one of
the determining factors in brain aging and performance as
well as a key factor in the development of neurodegenerative
diseases [36]. One of the harmful eﬀects of ROS is the
inactivation of enzymes of the citric acid cycle. Citric acid
cycle enzymes that are especially susceptible to oxidative
stress are the aconitase and the KGDHC [15, 37]. Aconitase
shows the highest susceptibility towards ROS, because of
its sulfur-iron complex, but aconitase inhibition remains
irrelevant if it does not exceed 90 percent (see Figure 9 and
[15]). KGDHC is tightly bound to the inner mitochondrial
membrane[38]andmightbepartofacitricacidcyclesuper-
complex [39]. It binds to complex I of the mitochondrial
respiratory chain [40], which might make it a prominent
target of ROS due to the close spatial proximity to the
ROS generating sites. Thus, ROS is one possible reason for
KGDHC deﬁciency.
There is no general agreement on the relative importance
of various proposed ROS producing sites of the RC. Depen-
dence of ROS production from the membrane potential
has been measured [41, 42]. Comparing these measured
characteristics with the occupation status of the disputed
ROS generating sites, modeling can help to identify or
excludesitesasrelevantproducersofROS(seeFigure5).Our
calculations show that the occupation state as function of the
membrane potential of the fully reduced ﬂavin, the SQn site
in complex I, and the SQp site in complex III, but not the
ﬂavin radical in complex I, and the SQn site in complex III,
is in agreement with measured dependencies. For complex
I, our ﬁndings are in agreement with experimental results
in [43] excluding the ﬂavin radical but showing the fully
reduced ﬂavin to act as ROS producing site of complex I. For
complexIII,ourﬁndingsareinagreementwithotherreports
(see, e.g. [44]).
Since KGDHC is especially susceptible to ROS, we exam-
ined if the reduction of KGDHC activity has an eﬀect on the
occupation state of the conﬁrmed relevant ROS producing
sites (Figure 10). We found that there is a signiﬁcant
decrease in the occupation state of the fully reduced ﬂavin
in complex I and SQp of complex III for all ATP demands,
that is, KGDHC inhibition reduces ROS production in the
respiratory chain by lowering the redox state of the mito-
chondrion. Since KGDHC itself is also an ROS producer and
ROS production by this enzyme decreases with decreasing
mitochondrialredoxstate[45],endogenousROSproduction
by KGHC is also reduced in case of KGDHC deﬁciency.
It has to be noted that our model does not include
the impairment of RC complexes by ROS as it has been
observed in neurodegenerative diseases (see, e.g., [46]). A
reduction in the activity of complex I results in increase
in ROS production [47]. Hence, structural and functional
impairment of the RC might override the inhibitory eﬀect
of reduced KGDHC on ROS production.
Here, we focused on the eﬀects of KGDHC inhibition
on the energy metabolism and showed that for a given
degreeofinhibitiontheimpairmentdependscruciallyonthe
functional state of the cell. For ROS production, KGDHC
inhibition alone does reduce the ROS generation in the
respiratory chain. Nevertheless, the detailed description of
the RC in our model provided further arguments for the
relative importance of ROS producing sites proposed in the
literature.
Taken together, our model helps to elucidate the causal
chain of molecular events connecting reduced KGDHC
activity to the energetic breakdown of neuronal cells during
development of neurodegenerative diseases.
Abbreviations
Fe-S: Iron sulfur
FMN: Flavin mononucleotide
KGDHC: α-ketoglutarate dehydrogenase
RC: Respiratory chain
ROS: Reactive oxygen species
SQ: Semi-ubiquinon
TCAC: Tricarbonic acid cycle/citric acid cycle
Q: Ubiquinon
QH2: Ubiquinol.
Acknowledgment
The project was in part funded by the German Systems
Biology Program “Virtual Liver,” Grant no. 0315741.
References
[1] D. S. Albers and M. Flint Beal, “Mitochondrial dysfunction
and oxidative stress in aging and neurodegenerative disease,”
Journal of Neural Transmission, Supplement, vol. 59, pp. 133–
154, 2000.
[2] G. E. Gibson, L. C. H. Park, K. F. R. Sheu, J. P. Blass, and N.
Y. Calingasan, “The α-ketoglutarate dehydrogenase complex
in neurodegeneration,” Neurochemistry International, vol. 36,
no. 2, pp. 97–112, 2000.
[3] G. E. Gibson, K. F. R. Sheu, J. P. Blass et al., “Reduced activities
of thiamine-dependent enzymes in the brains and peripheral
tissues of patients with Alzheimer’s disease,” Archives of
Neurology, vol. 45, no. 8, pp. 836–840, 1988.
[4] G. E. Gibson, H. Zhang, K. F. R. Sheu et al., “α-ketoglutarate
dehydrogenase in Alzheimer brains bearing the APP670/671
mutation,” Annals of Neurology, vol. 44, no. 4, pp. 676–681,
1998.
[5] F. Mastrogiacomo, C. Bergeron, and S. J. Kish, “Brain α-
ketoglutarate dehydrogenase complex activity in Alzheimer’s
disease,” Journal of Neurochemistry, vol. 61, no. 6, pp. 2007–
2014, 1993.
[6] R. F. Butterworth and A. M. Besnard, “Thiamine-dependent
enzyme changes in temporal cortex of patients with
Alzheimer’s disease,” Metabolic Brain Disease,v o l .5 ,n o .4 ,p p .
179–184, 1990.
[7] D. Terwel, J. Bothmer, E. Wolf, F. Meng, and J. Jolles,
“Aﬀected enzyme activities in Alzheimer’s disease are sensitive
to antemortem hypoxia,” Journal of the Neurological Sciences,
vol. 161, no. 1, pp. 47–56, 1998.
[8] P. Bubber, V. Haroutunian, G. Fisch, J. P. Blass, and G. E.
Gibson, “Mitochondrial abnormalities in Alzheimer brain:
mechanistic implications,” Journal of Neurochemistry, vol. 94,
articel 43, 2005.10 International Journal of Cell Biology
[9] N. Y. Calingasan, H. Baker, K. F. R. Sheu, and G. E. Gibson,
“Distribution of the α-ketoglutarate dehydrogenase complex
in rat brain,” Journal of Comparative Neurology, vol. 346, no. 3,
pp. 461–479, 1994.
[10] L. C. H. Park, N. Y. Calingasan, K. F. R. Sheu, and G. E.
Gibson, “Quantitative α-ketoglutarate dehydrogenase activity
staining in brain sections and in cultured cells,” Analytical
Biochemistry, vol. 277, no. 1, pp. 86–93, 2000.
[11] L. W. Ko, K. F. R. Sheu, H. T. Thaler, W. R. Markesbery,
and J. P. Blass, “Selective loss of KGDHC-enriched neurons
in Alzheimer temporal cortex: does mitochondrial variation
contribute to selective vulnerability?” Journal of Molecular
Neuroscience, vol. 17, no. 3, pp. 361–369, 2001.
[12] J.C.K.Lai,J.M.Walsh,S.C.Dennis,andJ.B.Clark,“Synaptic
and non synaptic mitochondria from rat brain: isolation and
characterization,” Journal of Neurochemistry, vol. 28, no. 3, pp.
625–631, 1977.
[ 1 3 ]H .M .H u a n g ,H .C .O u ,H .X u ,H .L .C h e n ,C .F o w l e r ,a n d
G. E. Gibson, “Inhibition of α-ketoglutarate dehydrogenase
complex promotes cytochrome C release from mitochondria,
caspase-3 activation, and necrotic cell death,” Journal of
Neuroscience Research, vol. 74, no. 2, pp. 309–317, 2003.
[14] G. Fiskum, A. Starkov, B. M. Polster, and C. Chinopoulos,
“Mitochondrial mechanisms of neural cell death and neuro-
protective interventions in Parkinson’s disease,” Annals of the
New York Academy of Sciences, vol. 991, pp. 111–119, 2003.
[15] L. Tretter and V. Adam-Vizi, “Inhibition of krebs cycle
e n z y m e sb yh y d r o g e np e r o x i d e :ak e yr o l eo fα-ketoglutarate
dehydrogenase in limiting NADH production under oxidative
stress,” Journal of Neuroscience, vol. 20, no. 24, pp. 8972–8979,
2000.
[16] D. F. S. Rolfe and G. C. Brown, “Cellular energy utilization
andmolecularoriginofstandardmetabolicrateinmammals,”
Physiological Reviews, vol. 77, no. 3, pp. 731–758, 1997.
[17] S. Chalmers and D. G. Nicholls, “The relationship between
freeandtotalcalciumconcentrationsinthematrixofliverand
brain mitochondria,” The Journal of Biological Chemistry, vol.
278, no. 21, pp. 19062–19070, 2003.
[18] M. R. Duchen, “Ca2+-dependent changes in the mitochon-
drial energetics in single dissociated mouse sensory neurons,”
Biochemical Journal, vol. 283, no. 1, pp. 41–50, 1992.
[19] F. Wu, F. Yang, K. C. Vinnakota, and D. A. Beard, “Computer
modeling of mitochondrial tricarboxylic acid cycle, oxidative
phosphorylation, metabolite transport, and electrophysiol-
ogy,” The Journal of Biological Chemistry, vol. 282, no. 34, pp.
24525–24537, 2007.
[20] O.V.Demin,B.N.Kholodenko,andH.V.Westerhoﬀ,“Kinetic
modeling of energy metabolism and superoxide generation in
hepatocyte mitochondria,” Molekulyarnaya Biologiya, vol. 35,
no. 6, pp. 1095–1104, 2001.
[21] G. Benzi, E. Arrigoni, F. Marzatico, and R. F. Villa, “Inﬂuence
of some biological pyrimidines on the succinate cycle during
and after cerebral ischemia,” Biochemical Pharmacology, vol.
28, no. 17, pp. 2545–2550, 1979.
[22] J. Folbergrova, B. Ljunggren, K. Norberg, and B. K. Siesjo,
“Inﬂuence of complete ischemia on glycolytic metabolites,
citric acid cycle intermediates, and associated amino acids in
the rat cerebral cortex,” Brain Research, vol. 80, no. 2, pp. 265–
279, 1974.
[23] D. P. Simpson and S. Angielski, “Regulation by bicarbonate
ion of intramitochondrial citrate concentration in kidney
mitochondria,” Biochimica et Biophysica Acta, vol. 298, no. 1,
pp. 115–123, 1973.
[24] M. J. Gibala, D. A. MacLean, T. E. Graham, and B. Saltin,
“Tricarboxylic acid cycle intermediate pool size and estimated
cycle ﬂux in human muscle during exercise,” American Journal
of Physiology, vol. 275, no. 2, pp. E235–E242, 1998.
[25] C. M. Smith, J. Bryla, and J. R. Williamson, “Regulation
of mitochondrial α ketoglutarate metabolism by product
inhibition a α ketoglutarate dehydrogenase,” The Journal of
Biological Chemistry, vol. 249, no. 5, pp. 1497–1505, 1974.
[ 2 6 ]J .M .G o r e l l ,M .M .L a w ,O .H .L o w r y ,a n dJ .A .F e r r e n d e l l i ,
“Levels of cerebral cortical glycolytic and citric acid cycle
metabolites during hypoglycemic stupor and its reversal,”
Journal of Neurochemistry, vol. 29, no. 2, pp. 187–191, 1977.
[27] R. G. Hansford and R. N. Johnson, “The steady state concen-
trations of coenzyme A SH and coenzyme A thioester, citrate,
and isocitrate during tricarboxylate cycle oxidations in rabbit
heart mitochondria,” The Journal of Biological Chemistry, vol.
250, no. 21, pp. 8361–8375, 1975.
[28] R. G. Hansford, “Studies on the eﬀects of coenzyme A-
SH: acetyl coenzyme A, nicotinamide adenine dinucleotide:
reduced nicotinamide adenine dinucleotide, and adenosine
diphosphate:adenosine triphosphate ratios on the intercon-
version of active and inactive pyruvate dehydrogenase in
isolated rat heart mitochondria,” The Journal of Biological
Chemistry, vol. 251, no. 18, pp. 5483–5489, 1976.
[29] G.C.BrownandM.D.Brand,“Proton/electronstoichiometry
of mitochondrial complex I estimated from the equilibrium
thermodynamic force ratio,” Biochemical Journal, vol. 252, no.
2, pp. 473–479, 1988.
[30] D. F. S. Rolfe, A. J. Hulbert, and M. D. Brand, “Characteristics
of mitochondrial proton leak and control of oxidative phos-
phorylationinthemajoroxygen-consumingtissuesoftherat,”
Biochimica et Biophysica Acta, vol. 1188, no. 3, pp. 405–416,
1994.
[31] G. Krishnamoorthy and P. C. Hinkle, “Non-ohmic proton
conductance of mitochondria and liposomes,” Biochemistry,
vol. 23, no. 8, pp. 1640–1645, 1984.
[32] A. Nicolli, A. Redetti, and P. Bernardi, “The K+ conductance
oftheinnermitochondrialmembrane:astudyoftheinducible
uniport for monovalent cations,” The Journal of Biological
Chemistry, vol. 266, no. 15, pp. 9465–9470, 1991.
[33] K. F. LaNoue and C. Doumen, “Studies of physiological
control of ATP synthesis,” Advances in Molecular and Cell
Biology, vol. 11, no. C, pp. 207–232, 1995.
[34] B. Chazotte and C. R. Hackenbrock, “Lateral diﬀusion as
a rate-limiting step in ubiquinone-mediated mitochondrial
electron transport,” The Journal of Biological Chemistry, vol.
264, no. 9, pp. 4978–4985, 1989.
[35] S. S. Santos, G. E. Gibson, A. J. L. Cooper et al., “Inhibitors
of the α-ketoglutarate dehydrogenase complex alter [1-
13C]glucose and [U-13C]glutamate metabolism in cerebellar
granule neurons,” Journal of Neuroscience Research, vol. 83, no.
3, pp. 450–458, 2006.
[36] A. Boveris and A. Navarro, “Brain mitochondrial dysfunction
in aging,” IUBMB Life, vol. 60, no. 5, pp. 308–314, 2008.
[37] H. A. Sadek, K. M. Humphries, P. A. Szweda, and L.
I. Szweda, “Selective inactivation of redox-sensitive mito-
chondrial enzymes during cardiac reperfusion,” Archives of
BiochemistryandBiophysics,vol.406,no.2,pp.222–228,2002.
[38] E. Maas and H. Bisswanger, “Localization of the α-oxoacid
dehydrogenase multienzyme complexes within the mitochon-
drion,” FEBS Letters, vol. 277, no. 1-2, pp. 189–190, 1990.
[39] A. E. Lyubarev and B. I. Kurganov, “Supramolecular organiza-
tion of tricarboxylic acid cycle enzymes,” BioSystems, vol. 22,
no. 2, pp. 91–102, 1989.International Journal of Cell Biology 11
[40] B.SumegiandP.A.Srere,“ComplexIbindsseveralmitochon-
drial NAD-coupled dehydrogenases,” The Journal of Biological
Chemistry, vol. 259, no. 24, pp. 15040–15045, 1984.
[41] A. A. Starkov and G. Fiskum, “Regulation of brain mitochon-
drialH2O2productionbymembranepotentialandNAD(P)H
redox state,” Journal of Neurochemistry,v o l .8 6 ,n o .5 ,p p .
1101–1107, 2003.
[42] S.MiwaandM.D.Brand,“Mitochondrialmatrixreactiveoxy-
gen species production is very sensitive to mild uncoupling,”
Biochemical Society Transactions, vol. 31, no. 6, pp. 1300–1301,
2003.
[43] L. Kussmaul and J. Hirst, “The mechanism of superoxide
productionbyNADH:ubiquinoneoxidoreductase(complexI)
from bovine heart mitochondria,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 103,
no. 20, pp. 7607–7612, 2006.
[44] D. Malinska, B. Kulawiak, A. P. Kudin et al., “Complex
III-dependent superoxide production of brain mitochondria
contributes to seizure-related ROS formation,” Biochimica et
Biophysica Acta, vol. 1797, no. 6-7, pp. 1163–1170, 2010.
[45] L. Tretter and V. Adam-Vizi, “Generation of reactive oxygen
speciesinthereactioncatalyzedbyα-ketoglutaratedehydroge-
nase,” Journal of Neuroscience, vol. 24, no. 36, pp. 7771–7778,
2004.
[46] P. M. Keeney, J. Xie, R. A. Capaldi, and J. P. Bennett,
“Parkinson’s disease brain mitochondrial complex I has
oxidatively damaged subunits and is functionally impaired
andmisassembled,”JournalofNeuroscience,vol.26,no.19,pp.
5256–5264, 2006.
[47] L. Tretter, I. Sipos, and V. Adam-Vizi, “Initiation of neuronal
damage by complex I deﬁciency and oxidative stress in
Parkinson’sdisease,”NeurochemicalResearch,vol.29,no .3,pp .
569–577, 2004.